Veru Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.02
- Today's High:
- $1.07
- Open Price:
- $1.06
- 52W Low:
- $0.93
- 52W High:
- $16.15
- Prev. Close:
- $1.05
- Volume:
- 473926
Company Statistics
- Market Cap.:
- $94.79 million
- Book Value:
- 0.385
- Revenue TTM:
- $15.02 million
- Operating Margin TTM:
- -854.5%
- Gross Profit TTM:
- $30.59 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -68.06%
- Return on Equity TTM:
- -145.9%
Company Profile
Veru Inc had its IPO on 1990-07-19 under the ticker symbol VERU.
The company operates in the Healthcare sector and Biotechnology industry. Veru Inc has a staff strength of 233 employees.
Stock update
Shares of Veru Inc opened at $1.06 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.02 - $1.07, and closed at $1.02.
This is a -2.86% slip from the previous day's closing price.
A total volume of 473,926 shares were traded at the close of the day’s session.
In the last one week, shares of Veru Inc have slipped by -1.92%.
Veru Inc's Key Ratios
Veru Inc has a market cap of $94.79 million, indicating a price to book ratio of 5.2161 and a price to sales ratio of 10.4686.
In the last 12-months Veru Inc’s revenue was $15.02 million with a gross profit of $30.59 million and an EBITDA of $-128114800. The EBITDA ratio measures Veru Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Veru Inc’s operating margin was -854.5% while its return on assets stood at -68.06% with a return of equity of -145.9%.
In Q2, Veru Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 65.2%.
Veru Inc’s PE and PEG Ratio
- Forward PE
- 117.6471
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.34 per share while it has a forward price to earnings multiple of 117.6471 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Veru Inc’s profitability.
Veru Inc stock is trading at a EV to sales ratio of 9.0802 and a EV to EBITDA ratio of -4.5256. Its price to sales ratio in the trailing 12-months stood at 10.4686.
Veru Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $75.20 million
- Total Liabilities
- $27.69 million
- Operating Cash Flow
- $5.97 million
- Capital Expenditure
- $25674
- Dividend Payout Ratio
- 0%
Veru Inc ended 2024 with $75.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $75.20 million while shareholder equity stood at $34.39 million.
Veru Inc ended 2024 with $0 in deferred long-term liabilities, $27.69 million in other current liabilities, 914204.00 in common stock, $-234895079.00 in retained earnings and $6.88 million in goodwill. Its cash balance stood at $16.21 million and cash and short-term investments were $16.21 million. The company’s total short-term debt was $2,118,595 while long-term debt stood at $9.28 million.
Veru Inc’s total current assets stands at $43.22 million while long-term investments were $4.44 million and short-term investments were $0. Its net receivables were $13.62 million compared to accounts payable of $18.12 million and inventory worth $6.49 million.
In 2024, Veru Inc's operating cash flow was $5.97 million while its capital expenditure stood at $25674.
Comparatively, Veru Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.02
- 52-Week High
- $16.15
- 52-Week Low
- $0.93
- Analyst Target Price
- $4
Veru Inc stock is currently trading at $1.02 per share. It touched a 52-week high of $16.15 and a 52-week low of $16.15. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $1.14 and 200-day moving average was $2.6 The short ratio stood at 13.36 indicating a short percent outstanding of 0%.
Around 2297.6% of the company’s stock are held by insiders while 3608.5% are held by institutions.
Frequently Asked Questions About Veru Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company’s drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition, its drug candidate also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.